Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried's strategy EVOLVE+, the new lab facility marks a key milestone in DINAMIQS' journey to becoming the leading CDMO in the ...
TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback